Back to Directory
Last Updated: 08/05/2026
Autifony Therapeutics
Stevenage
Founded 2011
Ion channel drug discovery platform for rare CNS disorders
Autifony Therapeutics is a clinical-stage UK biotech developing small molecule modulators of Kv3 voltage-gated potassium channels for rare genetic CNS disorders.
Lead programmes target Fragile X syndrome and rare myoclonic epilepsy syndromes, with preclinical work extending to schizophrenia, hearing loss, and neurodegenerative disease.
The company has partnered with Jazz Pharmaceuticals in a deal worth up to $770.5 million and maintains a collaboration with Boehringer Ingelheim.
Autifony was founded in 2011 as a GSK spinout.